DILRAJ GREWAL, MD
Ophthalmology Physician · CHICAGO, IL
Individual Active NPI 1437460656
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,073 | 18,962 | $3,972,349 | $1,418,667 | $1,096,939 |
| 2023 | 1,002 | 20,692 | $3,863,490 | $1,430,662 | $1,107,384 |
| 2022 | 1,065 | 8,458 | $3,623,494 | $1,364,057 | $1,051,446 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | 12,450 | $34 | $27 |
| 92134 | Imaging of retina | 1,916 | $37 | $27 |
| 92014 | Established patient complete exam of visual system | 1,688 | $117 | $81 |
| 67028 | Injection of drug into eye | 504 | $118 | $86 |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 385 | $195 | $155 |
| J0178 | Injection, aflibercept, 1 mg | 360 | $818 | $652 |
| J0177 | Injection, aflibercept hd, 1 mg | 336 | $307 | $245 |
| 92201 | Extended exam of the back part of the eye with retinal drawing | 188 | $23 | $16 |
| 67028 | Injection of drug into eye | 132 | $100 | $74 |
| J9035 | Injection, bevacizumab, 10 mg | 120 | $72 | $57 |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | 91 | $148 | $108 |
| 99204 | New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more | 86 | $156 | $112 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Ophthalmology Physician | 207W00000X | ✓ | 125-058261 | IL |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Ophthalmology Physician providers in Illinois
- NPI 1285740167
- NPI 1316525827
- NPI 1003826173
- NPI 1053522540
- NPI 1588657753
- NPI 1538963285
- NPI 1376171553
- NPI 1245531904
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.